GlobalData on MSN

First patient receives JANX014 dose in Janux’s trial for mCRPC

The trial involves a PSMA-directed T cell engager using Janux’s tumour-activated platform to activate T cells.
Cure Today

First Patient Enrolled in Phase 3 Recurrent Prostate Cancer Trial

The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...
Targeted Oncology

First Patient Dosed in VIR-5500 T-Cell Engager Trial in Metastatic Prostate Cancer

PRO-XTEN dual masking aims to keep the engager inactive in circulation, activate within tumor protease-rich microenvironments ...
Healio

Superior first-line prostate cancer treatment often not given due to ‘lack of awareness’

Please provide your email address to receive an email when new articles are posted on . Many men with metastatic hormone-sensitive prostate cancer have not received recommended first-line treatment.
Medscape

Few Prostate CT Simulations Successful on First Attempt

Only 31% of patients with prostate cancer receiving radiation therapy had a successful CT simulation on the first attempt, while more than half required multiple scans on the same day and nearly 17% ...
Business Insider

Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 IRVINE, California – ...
EurekAlert!

Innovative targeted therapy halts prostate cancer spread to the bone

New findings out of VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine show that an innovative drug effectively prevents prostate tumors from spreading to an advanced ...